Survival Outcomes after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in patients with Synchronous versus Metachronous onset of Peritoneal Metastases of Colorectal Carcinoma

Changes in Coagulation in Cancer Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Treatment (HIPEC)—A Systematic Review

“…1,2 Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is curatively intended and has improved the 5-year overall survival up to 58% for selected patients. [1][2][3][4][5][6][7][8][9] However, the prognosis depends on various factors such as tumor burden, extent of surgery, anatomical location of the primary tumor, and tumor histology. [1][2][3][4][5][6][7][8][9][10] Cytoreductive surgery involves resection of all visible cancer in the peritoneum often combined with resection of tumor-involved organs.…”

“…[1][2][3][4][5][6][7][8][9] However, the prognosis depends on various factors such as tumor burden, extent of surgery, anatomical location of the primary tumor, and tumor histology. [1][2][3][4][5][6][7][8][9][10] Cytoreductive surgery involves resection of all visible cancer in the peritoneum often combined with resection of tumor-involved organs. 11 When HIPEC is added, cytoreductive surgery is followed by perfusion of the abdominal cavity with a solution containing dextrose, saline, and chemotherapy.…”